Evidence map›Paper›PMID 37975972›Full record

ArticleCancer causes & control : CCC2024

Aspirin use and head and neck cancer survival and recurrence.

Xinman Zhang, Omar S Ilyas, Kayla R Getz, Laura S Rozek, Jeremy M G Taylor, Steven B Chinn, Gregory T Wolf, Alison M Mondul

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinman ZhangDepartment of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, USA.
Omar S IlyasDepartment of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, USA.
Kayla R GetzDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Laura S RozekSchool of Medicine, Department of Oncology, Georgetown University, Washington, DC, USA.
Jeremy M G TaylorDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Steven B ChinnDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor Michigan, USA.
Gregory T WolfDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor Michigan, USA.
Alison M MondulDepartment of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, USA. amondul@umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck cancer (HNC) has low 5-year survival, and evidence-based recommendations for tertiary prevention are lacking. Aspirin improves outcomes for cancers at other sites, but its role in HNC tertiary prevention remains understudied.

methodsHNC patients were recruited in the University of Michigan Head and Neck Cancer Specialized Program of Research Excellence (SPORE) from 2003 to 2014. Aspirin data were collected through medical record review; outcomes (overall mortality, HNC-specific mortality, and recurrence) were collected through medical record review, Social Security Death Index, or LexisNexis. Cox proportional hazards models were used to evaluate the associations between aspirin use at diagnosis (yes/no) and HNC outcomes.

resultsWe observed no statistically significant associations between aspirin and cancer outcome in our HNC patient cohort (n = 1161) (HNC-specific mortality: HR = 0.91, 95% CI = 0.68-1.21; recurrence: HR = 0.94, 95% CI = 0.73-1.19). In analyses stratified by anatomic site, HPV status, and disease stage, we observed no association in any strata examined with the possible exception of a lower risk of recurrence in oropharynx patients (HR = 0.60, 95% CI 0.35-1.04).

conclusionsOur findings do not support a protective association between aspirin use and cancer-specific death or recurrence in HNC patients, with the possible exception of a lower risk of recurrence in oropharynx patients.

Indexed as

AspirinHead and Neck NeoplasmsHumansProportional Hazards ModelsAspirinAspirinHead and neck cancerRecurrenceSurvival

Identifiers

PMID37975972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.